Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron, Inc. announced the activation of two new clinical sites for the currently enrolling ELPIS II Trial, evaluating Lomecel-B injection into the myocardium of infants with Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect.